Business
Viemed Healthcare Announces Principal Physician Researcher to Present Latest Clinical Findings
LAFAYETTE, La., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ: VMD and TSX: VMD.TO), a home medical equipment
About this update from Viemed Healthcare, Inc.
[{"type":"text","content":"LAFAYETTE, La., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ: VMD and TSX: VMD.TO), a home medical equipment supplier and the nation’s largest independent provider of ventilation that provides post-acute respiratory care services, announced today that the Company’s Chief Medical Officer, Dr. William Frazier, ABIM Board Certified in Internal, Pulmonary, Critical Care, and Sleep Disorders Medicine and leader of two peer reviewed clinical studies (the “recent studies”) concerning the benefits of Non-Invasive Ventilation at Home (NIVH) therapy in COPD-CRF patients, will be sharing his professional insights and perspective during a free public Webinar on December 9 at 12:00 p.m. EST. WEBINAR DETAILS EVENT: Learn how non-invasive ventilation at home treatment has proven to reduce healthcare utilization for COPD-CRF patients.WHAT: Complimentary Webinar with Viemed Chief Medical Officer, Dr. William Frazier, including live Q&A session immediately following study presentation.WHEN: Thursday, December 9, 2021, 12:00 p.m.-1:00 p.m. ESTWHERE: Virtual - Via ZoomHOW: RSVP HERE Research conducted in relation to the recent studies provides clear clinical evidence that patients with COPD-CRF who received NIVH had statistically significant and clinically meaningful reductions in hospitalizations and emergency department visits compared with patients not treated with NIVH. Furthermore, the data from such studies suggest that earlier NIVH treatment following a Chronic Respiratory Failure (CRF) diagnosis is associated with a considerable reduction in all-cause mortality. As Viemed’s Chief Medical Officer, Dr. Frazier has been on the vanguard of this therapy in the U.S., where currently only 5 percent of COPD eligible patients are utilizing NIVH, as compared to Europe and other parts of the world where it is more widely adopted. The recent studies and related Webinar are a timely educational resource following last month’s National COPD Awareness Month, sponsored by The National Heart, Lung, and Blood Institute, which cites COPD as a significant cause of disability and the nation’s fourth leading cause of death. “We believe these studies are groundbreaking U.S.-based medical evidence that set a gold standard, confirming that COPD-CRF patients who utilize NIVH therapy will live longer, go to the hospita...